{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-008178","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.569382+00:00","generated_at":"2026-05-24T22:56:39.519380+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ionis licenses sapablursen to Ono for $280M upfront, up to $660M milestones and mid-teen royalties","bullets":["$280M upfront payment; up to $660M in development, regulatory and sales milestones.","Sapablursen is an investigational RNA-targeted medicine for polycythemia vera; has FDA orphan drug and Fast Track designations.","Ono receives exclusive global rights; Ionis completes Phase 2 IMPRSSION study, Ono handles subsequent development and commercialization.","Ionis eligible for royalties in the mid-teen percentage range on annual net sales of sapablursen.","Transaction subject to Hart-Scott-Rodino Antitrust Improvements Act (HSR) review."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-008178","json":"https://secwatch.observer/filing/0001140361-25-008178.json","markdown":"https://secwatch.observer/filing/0001140361-25-008178.md","text":"https://secwatch.observer/filing/0001140361-25-008178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125008178/0001140361-25-008178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125008178/ef20045255_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:56:39.519380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}